Free Trial

Senti Biosciences (NASDAQ:SNTI) Upgraded by Wall Street Zen to Sell Rating

Senti Biosciences logo with Medical background

Senti Biosciences (NASDAQ:SNTI - Get Free Report) was upgraded by equities researchers at Wall Street Zen to a "sell" rating in a research report issued on Saturday.

A number of other equities research analysts also recently weighed in on the stock. Laidlaw began coverage on shares of Senti Biosciences in a research note on Friday, June 6th. They set a "buy" rating and a $5.00 price target for the company. Chardan Capital reissued a "buy" rating and set a $12.00 price objective on shares of Senti Biosciences in a research report on Thursday, June 12th.

Check Out Our Latest Stock Analysis on Senti Biosciences

Senti Biosciences Stock Performance

Shares of NASDAQ:SNTI traded down $0.09 during midday trading on Friday, hitting $1.89. The company's stock had a trading volume of 313,369 shares, compared to its average volume of 681,794. The stock has a market capitalization of $49.16 million, a price-to-earnings ratio of -0.17 and a beta of 2.09. The stock's 50 day simple moving average is $2.79 and its 200 day simple moving average is $3.43. Senti Biosciences has a fifty-two week low of $1.52 and a fifty-two week high of $16.94.

Senti Biosciences (NASDAQ:SNTI - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.85). The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $1.30 million. As a group, analysts anticipate that Senti Biosciences will post -14.54 EPS for the current year.

Institutional Investors Weigh In On Senti Biosciences

Hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC bought a new position in Senti Biosciences during the 4th quarter worth approximately $47,000. Renaissance Technologies LLC bought a new stake in shares of Senti Biosciences in the 4th quarter worth $181,000. Heights Capital Management Inc. bought a new stake in shares of Senti Biosciences in the 1st quarter worth $2,520,000. Finally, Nantahala Capital Management LLC purchased a new position in shares of Senti Biosciences in the 1st quarter worth about $2,984,000. 25.73% of the stock is currently owned by institutional investors and hedge funds.

Senti Biosciences Company Profile

(Get Free Report)

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.

Featured Articles

Should You Invest $1,000 in Senti Biosciences Right Now?

Before you consider Senti Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Senti Biosciences wasn't on the list.

While Senti Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Value Plays Set to Explode
5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines